ERA-NET PRIOMEDCHILD

Joint call for research projects on priority medicines for children

ERA-NET PRIOMEDCHILD
Call Text

EC Sixth Framework ERA-NET project PRIOMEDCHILD

Contents:

ERA-NET PRIOMEDCHILD

This document provides information about the first joint call for multinational research projects on Priority Medicines for Children within the framework of the ERA-NET PRIOMEDCHILD. The main purpose of the call is to contribute to more effective and safer medicines for children. The call focuses on two research topics: **"**The development or use of innovative methodology in medicines for children research" and "Innovation of paediatric formulations and drug delivery systems". The ERA-NET PRIOMEDCHILD funding organisations, hereafter called *Funding Partners*, which have agreed to participate in the Joint Call are listed in Table 1. Under the umbrella of PRIOMEDCHILD, the Funding Partners will jointly provide funds in the order of 8 million Euros to support the call (for individual country commitments please see National Annexes). Each national funding organisation will fund only the project participants from its own country. Research groups from non-funding countries may participate in projects if they are able to secure their own funding. Each proposal must involve a minimum of three participants from at least three countries of which two should be from Funding Partner countries (The Netherlands, Estonia, Finland, France, Great Britain, Italy, Latvia and Poland). The maximum number of participants in a consortium is 8. Regardless of its size, each collaborative consortium should have the optimal critical mass to achieve ambitious scientific goals and should clearly show the added value from working together.

The submission and evaluation of proposals will be performed in two stages. The first stage evaluation will consist of an eligibility check followed by a scientific evaluation by the Scientific Advisory Board (*i.e.* the evaluation panel) resulting in either invitation to submit a full proposal or rejection. The full proposals will be peer reviewed and the final decision on funding will be made by the National funding organisations according to the final ranking list provided by the Scientific Advisory Board.

The deadline for submission of pre-proposals is 7th January 2010. Selected pre-proposals will be invited to submit full proposals by 10th May 2010. Projects are expected to start in the last quarter of 2010, beginning of 2011.

Table 1. Funding Partners

Country	Partner
The Netherlands	The Netherlands Organisation for Health R&D
Estonia	The Estonian Science Foundation
Finland	The Academy of Finland
France	The French funding Agency - Agence Nationale de la Recherche
Great Britain	The Medical Research Council
Italy	The Italian National Institute of Health
Latvia	The Latvian Academy of Sciences
Poland	The National Centre for Research and Development

1 Purpose of the Call

The ERA-NET PRIOMEDCHILD is a partnership between research funding organisations to bring coherence and cooperation to national research programmes and policies on research on Priority Medicines for Children.

The goal of this ERA-Net is to coordinate research efforts of European and associated countries in the field of priority medicines for children. Over 50% of the medicines used in children may not have been studied in this age group. For the paediatric population (0-18 years), this means that medicines are used without proper information on dosage, potential toxicity and evidence of clinical safety and efficacy at the recommended dosages. The aim of the Call is to enable scientists/researchers in different countries to build an effective collaboration on a joint research project aiming at better medicinal treatments for children. The programme performance based on complementary expertise and high-level competencies of eligible participants will contribute to strengthening and streamlining national activities and public private cooperation on a European scale. Coordinated research towards better medicines for children should reduce the burden of childhood diseases and ensure that children are treated with sufficiently evaluated and effective medicines. Moreover, it should enhance the scientific excellence and finally eliminate a number of barriers against paediatric research.

2 General Call information

2.1 Call topics for research proposals

The research topics have been identified and fall into two major theme pillars addressing common issues:

- **The development or use of innovative methodology in medicines for children research**

  This theme focuses on research that will lead to the facilitation of the performance of clinical research and improved feasibility of studies in children either by decreasing individual invasiveness, size of the paediatric population exposed to drugs under investigation or by lessening the burden of clinical trials. This includes the rational use of already available data.

  Topics in this theme are ***for example***: PK/PD modelling and simulation (including sparse data approaches and the development of physiologically-based predictors of oral drug absorption); the development of novel approaches to assay drug and metabolite levels in low volume biological samples, the use of sequential approaches in dose-finding and efficacy trials; research on biomarkers and micro dosing with radio-active compounds in accelerator mass spectrometry (AMS) and positron emission tomography (PET); (observational) methods to evaluate either safety or efficacy (including long term outcome measures of special interest in children and quality of life endpoints); the development and validation of already used non-validated endpoints and biomarkers including for example non invasive imaging such as PET and (functional) magnetic resonance imaging (MRI); the validation of new methods, as Bayesians, to detect the predictive signal of risk and to assess the safety of drugs and other techniques including mechanistic studies to study safety and efficacy of medicines for children.

- **Innovation of paediatric formulations and drug delivery systems**

  The studies on novel modes of drug delivery (buccal, nasal, transdermal), age specific formulations, innovation on taste masking and improved dosing devices, risk assessment and data collection on excipients.

It is stressed that for both topics it is important that the ethical and informed consent issues regarding paediatric research are taken into account for the project proposals.

Topics that are eligible according to the FP7 call on Off-patent medicines will not be granted in the PRIOMEDCHILD Joint Call. For information on the FP7 call please visit the website of Cordis (http://cordis.europa.eu/fp7) and EMEA (http://www.emea.europa.eu/htms/human/paediatrics/prioritylist.htm). However, studies on specific medicinal products in the priority list may be performed provided the purpose of each study planned in the submitted projects is to develop the innovative methodological approaches for their evaluation.

2.2 Call timeline

This transnational call for proposals will involve a two-stage procedure, with the following timetable:

Procedure	**Time schedule**
Launch of the Call:	2nd November 2009
Submission deadline for pre-proposals:	7th January 2010
Communication of the pre-proposals evaluation results:	1th of March 2010
Submission deadline for full proposals:	10th May 2010
Deadline for rebuttals:	22nd June 2010
Communication of the funding decision:	September 2010
Start of selected projects:	November 2010-January 2011

2.3 Eligibility

Research projects will be funded for a maximum of 36 months. Joint transnational research proposals may be submitted by research groups from higher education institutions, non-university public research institutes, hospitals, parent-patient organizations as well as commercial companies, in particular small and medium-size enterprises. The eligibility of the aforementioned institutions, together with details of eligible costs (personnel, material, consumables, travel money, investments), are subject to National regulations. Please note that public-private partnerships are welcome. Also note that commercial companies are, for some funding organisations, not or only under certain conditions, eligible. Since the rules concerning funding of private partners vary, please contact the appropriate National Contact Person (Table 2) for more information.

Proposals should be submitted on time, and the language of the submitted proposal must be English. All research projects will be funded for a period of 36 months. Only multi-national projects will be funded.

Each proposal must involve a minimum of three participants from at least three different countries of which a minimum of two research participants should be from PRIOMEDCHILD Funding Partner countries (NL, EE, FI, FR, UK, IT, LV, PL). The maximum number of participants in a consortium is 8. Each applicant can only apply for funding once in the PRIOMEDCHILD call. Research groups from non-PRIOMEDCHILD countries or non-Funding Partners may participate in projects if they are able to secure their own funding. They must state clearly in the proposal if these funds are already secured or if not, how they plan to obtain funding in advance

to the start of the project. If the contribution of the third party is considered essential for the success of the entire proposal, the third party will be required to document the availability of their funds before the SAB meeting and Call committee meeting regarding the full proposals (tentatively 12-26 of July 2010).

3 Management boards

Two boards, the Call Committee and the Scientific Advisory Board, will manage the evaluation process of the call with support from the Joint Call Secretariat (set up at The Netherlands Organization for Health Research and Development, ZonMw).

i) The Call Committee (CC) is composed of a single representative from each Funding Partner. The CC will supervise the progress of the call and the evaluation of proposals. The CC will make the final funding recommendation to the national funding organisations on the proposals to be funded, based on the final ranking list provided by the SAB. All decisions concerning the call procedures will be taken by the CC.

ii) The Scientific Advisory Board (SAB) is a panel of internationally recognised scientific experts responsible for the evaluation of submitted proposals, and the monitoring and evaluation of funded projects. SAB members are nominated by the CC, according to scientific expertise relevant to the call. SAB members will not submit or participate in proposals within this call, and must sign a confidentiality form and a statement to confirm that they do not have any conflicts of interest. The SAB will nominate external peer reviewers. A chair and vice-chair will be chosen among SAB members.

4 Submission and evaluation of proposals

4.1 Submission of pre-proposals

Pre-proposals must be submitted in electronic form to the PRIOMEDCHILD Call Secretariat **before 7th of January 2010 15:00 hours GMT+1** (The Hague, The Netherlands time), and strictly follow the "Guidelines for applicants". The application forms and the guidelines will be available at **www.priomedchild.eu**. Applicants should take note of individual National rules, and should contact their National Contact Person for any questions.

Research project coordinators hereinafter referred to as project coordinators (applicant 1) should be identified for each research project and function as primary contact person for the research consortium. Please note that project coordinators should be from PRIOMEDCHILD funding partner countries. In addition, a principal investigator should be designated from each of the other collaborative institutions (applicants 2, 3, etc. up to 8). The decision on selection of applications for invitation to full proposal will be communicated by 1th of March 2010.

4.2 Evaluation of pre-proposals

The Joint Call Secretariat will check compliance of pre-proposals with the administrative criteria and subsequently will send the pre-proposals to the CC. The Call Committee members will perform an eligibility check in line with national criteria. The SAB will evaluate the pre-proposals and discuss them at a meeting resulting in either invitation to submit a full proposal or rejection. The CC will meet after the SAB meeting and will make the final decision upon the invitation of full proposal or rejection. Two or three times the number of potentially funded projects according to the Joint Call budget will be invited to submit a full proposal.

Evaluation of pre-proposals will be according to the following criteria:

- relevance to the aims and content of the Call;
- scientific innovation and excellence;
- addressing ethical issues;
- potential scientific and societal impact;
- feasibility of the project;
- quality of the consortium, added value of joint working including evidence of true cooperation within the collaboration.

4.3 Submission of full proposals

Full proposals must be submitted in electronic form to the PRIOMEDCHILD Call Secretariat **before 10th of May 2010 15:00 hours GMT+1** (The Hague, The Netherlands time), and strictly follow the "Guidelines for applicants". The application forms and the guidelines will be available at **www.priomedchild.eu**. Applicants should take note of individual National rules, and should contact their National Contact Person for any questions. The selection on full proposals will be communicated to applicants as soon as possible and before the end of September 2010.

The information given in the pre-proposal is binding. Thus, any fundamental changes between the pre- and full proposals, e.g. composition of the consortia, objectives of the project, must be communicated to the Joint Call Secretariat with detailed justification and will only be allowed by the CC under exceptional circumstances.

4.4 Evaluation of full proposals

4.4.1 Peer reviewing

Eligible full proposals will be sent out for external peer review to at least two reviewers. External reviewers will be instructed by a guideline for peer review and provided with an evaluation form (based on the criteria in 5.4.4). Proposals will be distributed to the reviewers by the Joint Call Secretariat in a way that the reviewers have no conflict of interest (according to the code of the Netherlands Organisation of Health Research and Development, ZonMw).

4.4.2 Rebuttal

Project coordinators will receive the anonymised peer reviews and will have the opportunity to respond, on behalf of all project partners, to the reviewers' comments and potential questions, within about one week

(deadline: **22nd June 2010**). This response is optional; a nil response does not exclude the proposal from the next stage of the review procedure. Rebuttals should be submitted as pdf-file to the Joint Call Secretariat. The response is strictly limited to a maximum of 2 A4 pages, margins of 2.5 cm with font Times New Roman size 11, line spacing of 1.5. Attachments or appendices are not permitted. All exceeding pages will be deleted regardless of the content. The purpose of the response is to enable the applicants to address technical queries and points of fact, and the response must be confined to these issues. In particular, the response must not discuss the competence, expertise or suitability of the reviewer. The response can only provide feedback on comments specifically raised by the referees and should not be used to otherwise introduce entirely new information.

4.4.3 Evaluation by the SAB

The SAB will meet to evaluate all eligible full proposals based on their expertise, the peer reviews, the rebuttals, and the discussions held at the panel meeting. Scoring and ranking of proposals will be performed through consensus by the SAB, using the criteria outlined in 5.4.4.

4.4.4 Criteria for evaluation of full proposals

Scientific quality:

- novel, innovative research within the scientific scope of the call and innovative potential of the expected results for industrial application where appropriate;
- scientific impact
- feasibility of project;
- quality of the consortium, scientific track record of applicants;

Relevance of project:

- transnational added value and complementarity of expertise;
- evidence of true cooperation within the research consortium and with groups and organizations outside the research consortium;
- addressing ethical issues
- economic and societal impact including plan for use and dissemination of knowledge
- adequateness and scientific justification of requested resources and financial requirements.

4.5 Decision

The Call Committee will select proposals for funding based on the final ranking list of the SAB and on available funding, after discussion with CC members' respective funding organisation. Final funding decisions will be made at the national level.

The Joint Call Secretariat will communicate to all project coordinators the final decisions together with the review from the SAB.

5 Financial and legal issues

5.1 Funding mode

The PRIOMEDCHILD Funding Partners have agreed to launch a joint call using the "virtual common pot" funding mode. This means that national funding will be made available through national funding organisations according to national funding regulations. Each country funds only its national component of the transnational research project. The funding rate within the call will be variable up to a maximum of 100% of the funds requested, according to national rules. These rates and additional national specifications will be provided in the applicants' guide.

Prior to submitting a proposal, applicants should verify their eligibility and the rate of financial support with their national funding organisation, and are recommended to contact their National Contact Person.

5.2 Final payment conditions

Individual funding organisations may retain the final payment for a project, according to national funding rules.

5.3 Contractual relationships

The PRIOMEDCHILD Call makes use of 'virtual common pot' funding, and this involves aligning the provisions of funding from each country around a common set of research needs. Because of the nature of the funding it is necessary for each funding partner to enter into a contract/letter of grant with the relevant researcher, but also to ensure that these contracts/letters of grants are synchronized both in time and content, so that the research group can deliver transnational outputs. The national funders have to make sure that common PRIOMEDCHILD conditions are met (e.g. common commencement date of a given project, reporting requirements etc.).

Proposals and any information relating to them shall be kept confidential within the PRIOMEDCHILD consortium. Proposals shall not be used for any purpose other than the evaluation of the applications, making funding decisions and monitoring of the projects. As part of the funding decision process it may be necessary to provide third parties e.g. other government organisations with information relating to the research project proposals. These third parties will be required to treat all information provided in a confidential manner. The permission of the Project Coordinator will be obtained prior to the submission of any information to these third parties. International experts are required to sign a confidentiality agreement prior to evaluating proposals.

Projects submitted to the second evaluation stage will be required to include a publishable summary of their proposal, which will clearly identify the composition of the consortium. If the project is offered funding, this information will be published on the PRIOMEDCHILD website. All other project details are kept strictly confidential.

5.4 Funding contracts/letter of grants

Each project includes several consortium members called Research Partners and one Project Coordinator. Each Research Partner (including the Project Coordinator) will have a separate funding contract/letter of grant according to national regulations with the appropriate national funding institutions.

Changes to the composition of research consortia or in budget cannot occur during the contract/letter of grant. Any changes in the work plan should be only minor but will need to be authorised by the CC before amendment to the contract/letter of grant by the funding bodies can be issued. The Research Partners shall inform the Call Secretariat and the funding bodies of that project of any event that might affect the implementation of the project.

A project can commence as soon as the Joint Call Secretariat has acknowledged receipt of the copies of the signed National Funding Contracts/letter of grants of all Research Consortium partners within 2-3 months. Once the national contract/letter of grant comes into effect, eligible costs may be claimed as per national procedures. In the interim period, researchers may commence work on the project at their own risk and costs.

5.5 Research consortium agreement

It is mandatory for funded research groups to draw up a Consortium Agreement, in order to manage the delivery of the project activities, finances etc. and to avoid disputes which might be damaging to the completion of the project.

It will be the responsibility of the Project Coordinator. The Consortium Agreement will normally be under the law and legal system of the country of the Project Coordinator. The purpose of this document will be:

- to underpin the researchers' collaboration and provide the researchers with mutual assurance on project management structures and procedures, and their rights and obligations towards one another and;
- to assure the research funders that the consortium has a satisfactory decision making capability and is able to work together in a synergistic manner.

The following subjects (as a minimum) should be addressed by the Consortium Agreement:

- purpose of and definitions used in the Consortium Agreement;
- names of organisations involved;
- organisation and management of the project;
- role and responsibilities of the project coordinator and the research partners: person in charge, their obligations and key tasks, conditions for their change;
- deliverables (transnational reports and if relevant requirements for national reports where co-ordination is required);
- resources and funding;
- confidentiality and publishing;
- Intellectual Property Rights (how this issue will be handled between partners);
- decision making within the consortium;
- handling of internal disputes;
- the liabilities of the partners towards one another (including the handling of default of contract/letter of grant).

5.6 Ownership of intellectual property rights and data management

Results and new Intellectual Property Rights (IPR) resulting from projects funded through the PRIOMEDCHILD Joint Call will be owned by the researchers' organisations according to national rules on IPR. If several participants have jointly carried out work generating new IPR, they shall agree amongst themselves as to the allocation of ownership of IPR, taking into account their contributions to the creation of those IPR as well as the European guidelines on IPR issues (http://ec.europa.eu/research/fp6/ model-contract/pdf/fp6-iprguidelines_en.pdf).

The results of the research project and IPR created should be actively exploited and made available for use, whether for commercial gain or not, in order for public benefit to be obtained from the knowledge created. The Funding Partners shall have the right to use documents, information and results submitted by the Research Partners and/or to use the information and results for their own purposes, provided that the owner's rights are kept and taking care to specify their origin.

6 Contact and further information

The Joint Call Secretariat will be set up at ZonMw (The Netherlands Organization for Health Research and Development) to assist the CC and the national funding bodies during the implementation of the call and the follow-up phase until the funded research projects have ended. The Joint Call Secretariat will be responsible for the administrative management of the call. It will be the primary point of contact referring to the call procedures between the research consortia, the funding organisations (CC) and the peer reviewers.

The only official communication line of the proposal is between the Joint Call Secretariat and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to the other participants.

Further information on the PRIOMEDCHILD Project, the Call and the follow-up is available at the PRIOMEDCHILD website (**www.priomedchild.eu**). It is advised to contact the National Contact Person for any questions regarding the Call.

Table 2: National Contact Persons

Country	Partner	Website	National Contact Person
The Netherlands *Joint Call Secretariat*	The Netherlands Organisation for Health R&D	www.zonmw.nl	Deborah Alfarez **alfarez@zonmw.nl** +31 70 3495140
Estonia	The Estonian Science Foundation	www.etf.ee	Iige Maalmann **iige@etf.ee** +372 6996213
Finland	The Academy of Finland	www.aka.fi	Maiju Gyran **maiju.gyran@aka.fi** +358 9 7748 8291
France	The French funding Agency - Agence Nationale de la Recherche	www.agence-nationale-recherche.fr/	Jenifer Clark **Jenifer.Clark@agencerecherche.fr** +33 1 78 09 80 78
Great Britain	The Medical Research Council	www.mrc.uk	Carolina Mailhos +44 20 76705296 scientific queries: **carolina.mailhos@headoffice.mrc.ac.uk** eligibility queries: **admin.eaa@headoffice.mrc.ac.uk**
Italy	The Italian National Institute of Health	www.iss.it	Pietro Panei **panei@iss.it** + 39 06 499020 83
Latvia	The Latvian Academy of Sciences	www.lza.lv	Ieva Cipruse **ieva.cipruse@lza.lv** +371 67227790
Poland	The National Centre for Research and Development	www.ncbir.gov.pl	Bogdan Podwysocki **b.podwysocki@ncbir.gov.pl** +48 22 583 05 01

7 Monitoring research project performance and dissemination

7.1 Monitoring and reporting requirements

The coordinators of all the funded projects must submit annual scientific project reports and a final scientific project report (within six months of the end of the project) to the Joint Call Secretariat. All reports must be in English and use a common report form that will be provided. The Research Partners are jointly responsible for delivery of the reports, and the Joint Call Secretariat will only accept reports delivered on behalf of the consortium, via the Project Coordinator.

In addition, the Project Coordinators could be asked to present the progress of their projects at mid-term or final dissemination events.

Each participant should submit financial and scientific reports to their national funding organisations, according to national regulations. The progress and final results of each individual contract/letter of grant will be monitored by the respective national funding organisations through the achievement of milestones.

7.2 Dissemination of results

Dissemination of project results is requested in terms of both scientific papers, presentations and seminars to ensure direct information transfer for stakeholders. A detailed dissemination plan should specify the intended activities. All dissemination activities should be mentioned in the final report.

Project partners are required to refer to PRIOMEDCHILD in publications, exhibitions, lectures and press information concerning results of the PRIOMEDCHILD projects. Furthermore, all publications deriving from the PRIOMEDCHILD have to be uploaded on **www.priomedchild.eu**.

To demonstrate the added value of transnational cooperation projects, results from the Joint Call shall be disseminated. This can be done via different channels, e.g.:

- High level conferences with relevant stakeholders to inform widely about the project results;
- Publication of a short outline of funded projects on PRIOMEDCHILD and national/regional websites;
- Press conferences and workshops.

COORDINATION OF RESEARCH ON PRIORITY MEDICINES FOR CHILDREN

National eligibility criteria

ANNEX to ERA-NET PRIOMEDCHILD Call Text

ERA-NET PRIOMEDCHILD

The Netherlands

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the ZonMw version of the call (www.zonmw.nl/subsidie/subsidiekalender)

Funding organisation	De Nederlandse Organisatie voor gezondheidsonderzoek en zorginnovatie (ZonMw) http://www.zonmw.nl
Contact person	**Dr. Deborah Alfarez** ZonMw, Tel.: +31 (0) 70 349 5140, e-mail:alfarez@zonmw.nl
Funding commitment	3.0 Mio. €
Maximum amount of funding for Dutch research group(-s) in a proposal	About 350.000 €
Anticipated number of funded research groups	6-9
Eligible institutions	legal body: university, university hospital, non-university public research institute, industry (note: industry is funded with a maximum of 50-60% of the total project cost)
Additional eligibility criteria	none
Eligible costs	personnel, consumables, animals, subcontracts, equipment, travels, documentation
Funding rates	Public organizations will be funded 100%. In the case of enterprises the funding rates will be applied according to the EC state aid rules. The funding rate depends on the size of the enterprise and the type of activity. SME/Medium sized enterprise Industrial research 75%, experimental development 50% SME/ Small enterprise Industrial research: 80%; Experimental development 60% For more information we refer to the ZonMw subsidievoorwaarden document on the **ZonMw website**

Estonia

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the Estonian version of the call (http://www.etf.ee/index.php?page=147&)

Funding organisation	Estonian Science Foundation www.etf.ee
Contact person	**Ms. Iige Maalmann** ETF: Endla 4, 10142 Tallinn, Estonia phone:+372 699 6213, e-mail: iige@etf.ee
Funding commitment	220 k €
Maximum amount of funding for Estonian research group(-s) in a proposal	Not defined
Anticipated number of funded research groups	2-3
Eligible institutions	All legal bodies
Additional eligibility criteria	Principal investigator • PhD (awarded by the deadline of submission of the application, at the latest) • at least three high level publications published within the last five years (which comply with the requirements of clauses 1.1, 1.2, 2.1 and 3.1 of the classification of publications of the Estonian Research Portal ETIS)
Eligible costs	According to the 'Rules of the Budget of Grant Project' http://www.etf.ee/public/files/Rules%20of%20the%20Budget%20of%20Grant%20Project.pdf

Funding rates	Estonian Science Foundation uses additional cost model: 100% of additional costs will be eligible.

ERA-NET PRIOMEDCHILD

Finland

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the Finnish version of the call (http://www.aka.fi/fi/A/Suomen-Akatemia/Kansainvalisyys_/ERA-NETit/PriomedChild/

Funding organisation	Academy of Finland
Contact person	**Maiju Gyran** Academy of Finland, Health Research Unit, Vilhonvuorenkatu 6, 00501 Helsinki, Finland phone:+358 9 77 48 82 91, e-mail: maiju.gyran@aka.fi
Funding commitment	500k €
Maximum amount of funding for Finnish research group(-s) in a consortium	Around 250k €
Anticipated number of funded research groups	2
Eligible institutions	see Academy's web page: http://www.aka.fi/en-gb/A/For-researcher/How-to-apply/Application-guidelines/General-application-guidelines/
Additional eligibility criteria	-
Eligible costs	see Academy's web page: http://www.aka.fi/en-gb/A/For-researcher/How-to-apply/Application-guidelines/General-application-guidelines/
Funding rates	The Academy will apply the full cost model when making decisions regarding applications submitted to calls opened in 2009 and later including ERA-NET calls. For more information, please see Academy's web page : http://www.aka.fi/en-gb/A/For-researcher/How-to-apply/Full-cost-model/

ERA-NET PRIOMEDCHILD

France

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the French version of the call (**http://www.agence-nationale-recherche.fr/AAPProjetsOuverts**)

Funding organisation	ANR, Agence Nationale de la Recherche www.agence-nationale-recherche.fr
Contact person	**Dr. Jenifer Clark** Agence Nationale de la Recherche, 212 rue de Bercy, 75012 Paris, France phone: +33 1 78 09 80 78, e-mail: jenifer.clark@agencerecherche.fr
Funding commitment	1.5 Mio. €
Maximum amount of funding for French research group(-s) in a consortium	Not defined
Anticipated number of funded research groups	approximately 8 projects
Eligible institutions	Applicants from public research institutes such as EPST, EPIC, universities, hospitals, etc. or from private bodies such as industries, large or SMEs, etc. are all eligible to apply. The coordinator must belong to a public research organisation.
Additional eligibility criteria	Please download online the specific annexe document for research groups applying to the Priomedchild call for proposals for funding in France : http://www.agence-nationale-recherche.fr/AAPProjetsOuverts
Eligible costs	Personnel, consumables, animals, subcontracts, small equipment, travel, documentation
Funding rates	Please download online e the specific annexe document for research groups applying to the Priomedchild call for proposals for funding in France : http://www.agence-nationale-recherche.fr/AAPProjetsOuverts

ERA-NET PRIOMEDCHILD

Great Britain

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the MRC website (...)

Funding organisation	Medical Research Council
Contact person	**Dr. Carolina Mailhos** 20 Park Crescent, London W1B 1AL, UK phone: +44 02 7670 5170, e-mail : carolina.mailhos@headoffice.mrc.ac.uk
Funding commitment	£ 1.000.000
Maximum amount of funding for UK research group(-s) in a consortium	Around £ 330,000 per 36 month proposal
Anticipated number of funded research groups	2-3
Eligible institutions	Please refer to our applicant's handbook http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC001873
Additional eligibility criteria	-
Eligible costs	Please refer to the applicant handbook http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC001873
Funding rates	Applications must detail the full econmic cost of the research propsal as required under FEC. For more details please refer to the applicant handbook http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC001873

Italy

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person.

Funding organisation	Istituto Superiore di Sanità
Contact person	**Dr. Pietro Panei** ISS Viale Regina Elena, 300, 162 Rome Italy phone: 0039 06 499020 83, e-mail: panei@iss.it
Funding commitment	500-1000 k €
Maximum amount of funding for Italian research group(-s) in a consortium	
Anticipated number of funded research groups	3
Eligible institutions	
Additional eligibility criteria	
Eligible costs	
Funding rates	

Latvia

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the Latvian version of the call (...)

Funding organisation	Latvian Academy of Sciences
Contact person	**Dr. Maija Bundule** LAS, Akademijas laukums 1 phone:+371 67227790, e-mail: maija.bundule@lza.lv
Funding commitment	400 k €
Maximum amount of funding for Latvian research group(-s) in a consortium	Between 100 000 € and 150 000 €
Anticipated number of funded research groups	2
Eligible institutions	Legal bodies: universities, state research institutes and other research institutions listed in the register of research institutions and industry
Additional eligibility criteria	SME and industry may take part in the project with their own funding
Eligible costs	Personnel costs, direct costs such as consumables, equipment, reagents, animals and etc., subcontracts, travels, project management and overheads, which can reach a maximum of 10% of the total project costs
Funding rates	Maximum public funding intensity is applied under the provisions of Commission Regulation (EC) No 800/2008 of 6 August 2008 declaring certain categories of aid compatible with the common market in application of Articles 87 and 88 of the Treaty

ERA-NET PRIOMEDCHILD

Poland

Please note that country specific requirements might apply to this call. For further information see links or speak with the national contact person. See also the Polish version of the call eligibility criteria (http://www.ncbir.pl/pmc)

Funding organisation	National Centre for Research and Development/Narodowe Centrum Badań i Rozwoju
Contact person	**Dr. Bogdan Podwysocki** NCBiR, Narodowe Centrum Badań i Rozwoju, ul. Ks. I.J. Skorupki 4, 00-546 Warszawa phone: +48 22 583 05 01, e-mail: b.podwysocki@ncbir.gov.pll
Funding commitment	750 k €
Maximum amount of funding for Polish research group(-s) in a consortium	Up to 250.000 €
Anticipated number of funded research groups	2-3
Eligible institutions	Scientific entities – conducting scientific researches or development works in the continuous manner: - main organizational units of universities; - institutes established by the Polish Academy of Sciences; - R&D units (branch research units) - international institutes of science established according to separate provisions; - entities having the status of the R&D centre; - Polish Academy of Arts and Sciences; - other entities which have legal personality and the registered office in Poland.

Additional eligibility criteria	Enterprises are obliged to prove that they conduct R&D activities in the continuous manner. Enterprises are obliged to observe state aid provisions and to provide information on received state aid according to the regulation of the Council of Ministers of 20 March 2007 on information on received state aid and information on not received aid.
Eligible costs	The range of eligible costs comprises direct costs as: personnel costs, amortisation of the research equipment, materials, travel, subcontracting and indirect costs (overheads) limited up to 20% of direct eligible costs.
Funding rates	Public organizations will be funded 100%. In the case of enterprises the funding rates will be applied according to the EC state aid rules. The funding rate depends on the size of the enterprise and the type of activity: Large enterprise – Industrial research 65%, experimental development 40% Medium sized enterprise - Industrial research 75%, experimental development 50% Small enterprise - Industrial research: 80%; Experimental development 60%